Clinical Trials & COVID-19

Targeted HER2 Macrophage Cell Treatment

What is the study treatment?

The study treatment (CT-0508) is designed to target HER2 protein overexpression, which can cause cancer cells to rapidly grow and form solid tumors. The study treatment is made from your own macrophage cells, which are a type of immune cell that helps protect you from infections.

For the combination substudy, participants will also receive Pembrolizumab in combination with CT-0508 at the start of the study and then every 21 days thereafter until treatment completion.

Macrophage cells can also help the immune system guard against cancer. However, once a cancer starts to grow and spread, the macrophages and other cells in your immune system may not be powerful enough to effectively recognize and attack all the tumor cells. The macrophage cell therapy may help support your body’s immune system in its fight against different kinds of cancer, such as the following:

  • Breast cancer
  • Prostate cancer
  • Head and Neck cancer
  • Gastro-esophageal cancer
  • Lung cancer (small cell and non-small cell)
  • Colorectal cancer
  • Ovarian cancer
  • Endometrial cancer
  • Pancreatic cancer
  • Urethral/bladder cancer
  • Gallbladder cancer
HER2 Overexpression

What is an investigational cancer treatment?

An “investigational” cancer treatment is a treatment that has not been approved as a standard treatment. These treatments are still being investigated in clinical trials to make sure they are safe, tolerable and effective.

Regulatory authorities, such as the US Food and Drug Administration (FDA), must approve all investigational treatments before they can be used to treat cancer as well as any other diseases or disorders.

About Clinical Trials